Sheran Sharafi

Representative matters include:

Represented Aerovate Therapeutics, Inc. (Nasdaq:AVTE) in its reverse merger with Jade Biosciences, Inc. and the $300 million concurrent financing (April 2025)*

Represented Scienture LLC in its business combination with TRxADE Health Inc. (Nasdaq:MEDS) (September 2024)*

Represented AVROBIO, Inc. (Nasdaq:AVRO) in its:*

• Reverse merger with Tectonic Therapeutics, Inc., including contingent value rights (CVRs) and the concurrent private placement (June 2024)
• Sale of its Cystinosis gene therapy program for $87.5 million to Novartis (NYSE:NVS) (May 2023)

Represented Immunome Inc. (Nasdaq:IMNM) in its acquisition of certain assets of Atreca Inc. (Nasdaq:BCEL) for $5.5 million upfront cash and contingent value rights (CVRs) (May 2024)*

Represented Arrowroot Acquisition Corp (Nasdaq: ARRW) in its business combination with iLearningsEngines (April 2024)*

Represented Graphite Bio, Inc. (Nadaq:GPRH) in its reverse merger with LENZ Therapeutics and the $53.5 million concurrent private placement (March 2024)*

Represented EryDel in its cross-border sale to Quince Therapeutics (Nasdaq:QNCX) (October 2023)*

Represented Ikena Oncology Inc. (Nasdaq:IKNA) in its acquisition of Pionyr Immunotherapeutics in an all-stock transaction and contingent value rights (CVRs) (August 2023)*

Represented TCR2 Therapeutics (Nasdaq:TCRR) in its cross-border, all stock combination with Adaptimmune Therapeutics (Nasdaq:ADAP) (June 2023)*

Represented BJ's Wholesale Group (NYSE:BJ) in its acquisition of assets and operations of four distribution centers and the related private transportation fleet from Burris Logistics (January 2022)*

Represented Trillium Therapeutics, Inc. (Nasdaq/TSX:TRIL) in its $2.26 billion sale to Pfizer Inc. (NYSE:PFE) (November 2021)*

*Matters worked on prior to joining White & Case.